Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metabolon Launches Strategic Outsourcing Programs Focused On Disease Metabolism

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Metabolon’s partners will collaborate toward shared objectives through this program.

Metabolon, Inc. has announces the launch of its Disease Metabolism Strategic Outsourcing Program.

Through this program, Metabolon’s partners will collaborate toward shared objectives such as identifying novel targets, establishing high resolution phenotypic screening platforms, elucidating drug mechanism of action, discovering and validating pharmacodynamic biomarkers for translation to the clinic and for patient stratification.

Partners will have access to dedicated scientific, technical and IT staff at Metabolon, along with the company’s proprietary disease ontologies, as well as supporting visualization tools for the integration of metabolomics data with existing or data derived from such disciplines as genomics and proteomics.

John Ryals, Metabolon President and CEO, said, “We are excited to launch our Strategic Outsourcing Program as it represents a step change in the way the industry will think about and use metabolomics. This initiative results from years of research and development at Metabolon and has been requested by our industrial clients to fully exploit the potential of our platform. We believe that integrating metabolomic profiling deeply at the various stages of the R&D trajectory will lead to better targets, higher quality molecules, faster time to the clinic and reduced R&D risk and cost.”

Metabolon has completed hundreds of projects including those in oncology and metabolic disorders, and has acquired vast institutional knowledge of the metabolic pathways and targets that are involved in the onset of disease and its progression.

This new program offers a turnkey metabolism center of excellence that provides pharmaceutical and biotech partners access to the most advanced metabolomics research platforms, which serve to enhance their drug discovery and development efficiency.

Metabolon’s platform yields actionable insight into key disease metabolic processes, drug action, and patient response.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metabolon Files Patent Infringement Lawsuit against Stemina
The lawsuit requests monetary damages as well as an order permanently enjoining Stemina from continued acts of infringement.
Tuesday, August 28, 2012
Metabolon Strengthens Metabolomics Leadership with Acquisition of Lipomics Technologies
Gains proprietary lipids technology platform and further opportunities for diagnostics, personalized medicine and commercial services.
Friday, August 03, 2012
Metabolon Technology Now Available in Germany
The Helmholtz Zentrum Muenchen, Research Center for Environmental Health in Neuherberg, Germany, has successfully completed Metabolon’s validation requirements.
Friday, July 13, 2012
Metabolon’s Shanghai Jiao Tong University Lab Receives Validation
The joint metabolomics laboratory passed the quality control processes and has officially started operation.
Monday, May 14, 2012
Takeda and Metabolon Initiate Research Collaboration
Multiyear research alliance to discover novel targets and biomarkers.
Wednesday, April 18, 2012
Metabolon Awarded Analytical Methods Patent
The patented method enables the researcher to process, analyze and interpret data more efficiently.
Thursday, March 29, 2012
Metabolon Receives Accreditation by College of American Pathologists
Metabolon, Inc. announces that they have received laboratory accreditation from the College of American Pathologists (CAP).
Tuesday, December 06, 2011
Metabolomics Insight into Periodontal Disease Published in the Journal of Dental Research
Data reveal altered host-bacteria interactions associated with periodontitis.
Monday, October 24, 2011
Metabolon and SJTU Open Metabolomics Lab in China
Shanghai facility is company’s first foray into Asia.
Tuesday, October 18, 2011
Genome Wide Association Study Published in Nature
Metabolon, Inc. announces the publication of “Human Metabolic Individuality in Biomedical and Pharmaceutical Research” in the journal Nature.
Tuesday, September 20, 2011
Metabolon Secures $13 Million in Series D Financing
New investor Keating Capital, Inc. joins existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round.
Tuesday, August 30, 2011
Two Studies Provide Insight into Kidney Cancer
Metabolon, Inc. announces the publication of studies in two peer-reviewed journals that support the use of metabolomics in the diagnosis and treatment of kidney cancer.
Tuesday, August 16, 2011
Research into Dietary Leucine
Metabolon, Inc. announces the publication of “Dietary Leucine - An Environmental Modifier of Insulin Resistance Acting on Multiple Levels of Metabolism” in PLoS One.
Tuesday, July 19, 2011
USPTO Grants Two New Patents to Metabolon
Metabolon currently holds 17 US Patents related to its biochemical profiling methods, data analysis solutions and biomarkers for disease and toxicity.
Monday, June 20, 2011
Metabolon Awarded Patent in Metabolomics Methods for Drug Discovery
Metabolon, Inc. announces that it was awarded US Patent 7,910,301 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office.
Tuesday, May 17, 2011
Scientific News
New ACE-inhibiting Molecule Found in the Asparagus
Scientists have determined that sulfur-containing compounds in plants can inhibit ACE.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Shedding Light On Century-Old Biochemical Mystery
Yale scientists have used magnetic resonance measurements to show how glucose is metabolized in yeast to answer the puzzle of the “Warburg Effect.”
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Metabolon and BCM Show Metabolomics May Play Key Role in Precision Medicine
Metabolon’s technology enhances understanding of genetic data and improves health assessment in newly published study.
Newly Discovered Cells Restore Liver Damage in Mice Without Cancer Risk
The liver is unique among organs in its ability to regenerate after being damaged. Exactly how it repairs itself remained a mystery until recently, when researchers supported by the NIH discovered a type of cell in mice essential to the process
Study Finds Cutting Dietary Fat Reduces Body Fat More than Cutting Carbs
In a recent study, restricting dietary fat led to body fat loss at a rate 68 percent higher than cutting the same number of carbohydrate calories when adults with obesity ate strictly controlled diets.
Inappropriate Medical Food Use in Managing Patients with a Type of Metabolic Disorder
Researchers have proposed that there is a need for more rigorous clinical study of dietary management practices for patients with IEMs, including any associated long-term side effects, which may in turn result in the need to reformulate some medical foods.
Medical Researchers a Step Closer to Developing Anti-Obesity Pill
A weight loss pill could soon be possible thanks to the work of Deakin University medical researchers.
Engineered Bacterium Produces Important Industrial Chemical
A Korean research team has reported the production of 1,3-diaminopropane via fermentation of an engineered bacterium.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!